US · Healthcare · Drug Manufacturers - General
EPS came in at 0.96 against a street estimate of 0.82 — a beat of 17.1%.
Analysts rate Novo Nordisk A/S a buy (5 buy, 5 hold, 2 sell out of 12) with an average price target of $47.23.
| Fund | Stake |
|---|---|
| Dodge & Cox | 0.46% |
| Loomis, Sayles & Company LP | 0.42% |
| Franklin Templeton Inc | 0.36% |
| Susquehanna International Group, LLP | 0.25% |
| T. Rowe Price Associates, Inc. | 0.25% |
| Morgan Stanley - Brokerage Accounts | 0.25% |
| Bank of America Corp | 0.24% |
| Capital Research & Mgmt Co - Division 3 | 0.22% |
| Action | Detail | Date |
|---|---|---|
| Dividend | $0.58 / share ex-date Aug 17, 2026 · pay Aug 25, 2026 | 2026-08-17 |
| Dividend | $1.27 / share ex-date Mar 30, 2026 · pay Apr 8, 2026 | 2026-03-30 |
| Dividend | $0.58 / share ex-date Aug 18, 2025 · pay Aug 26, 2025 | 2025-08-18 |
| Split | 2 : 1 effective Sep 20, 2023 | 2023-09-20 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Novo Nordisk A/S — free to start.
Google PlayApp StoreData updated 2026-09-18.